1. Ambrosch A, Luber D, Klawonn F, Kabesch M. Focusing on severe infections with the respiratory syncytial virus (RSV) in adults: risk factors, symptomatology and clinical course compared to influenza A/B and the original SARS-CoV-2 strain. J Clin Virol. 2023;161: 105399. https://doi.org/10.1016/j.jcv.2023.105399.
2. Quarg C, Jörres RA, Engelhardt S, Alter P, Budweiser S. Characteristics and outcomes of patients hospitalized for infection with influenza, SARS-CoV-2 or respiratory syncytial virus in the season 2022/2023 in a large German primary care centre. Eur J Med Res. 2023;28(1):568. https://doi.org/10.1186/s40001-023-01482-z.
3. German Respiratory Society [Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin]. Position Paper on RSV Vaccination for Particularly Vulnerable Patients of the German Respiratory Society [Positionspapier Zur RSV-Schutzimpfung Bei Besonders Gefährdeten Patientinnen Und Patienten Der Deutsche Gesellschaft Für Pneumologie Und Beatmungsmedizin e.V.]. 2023. Accessed May 2, 2024. https://www.pneumologie.de/storage/app/uploads/public/654/231/5d4/6542315d4db67032864384.pdf. Accessed 2 May 2024.
4. Saxon Vaccination Commission [Sächsische Impfkommission]. 7. Position Paper of the SIKO - RSV Vaccination [7. Positionspapier Der SIKO – RSV-Impfung]. 2023. https://www.slaek.de/media/dokumente/patient/gesundheitsinformationen/impfen/SIKO_Positionspapier-zur-RSV-Impfung_final_2023-11-01.pdf. Accessed 3 Dec 2024.
5. Savic M, Penders Y, Shi T, Branche A, Pirçon J. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2022;17(1): e13031. https://doi.org/10.1111/irv.13031.